Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
Type:
Grant
Filed:
June 16, 2021
Date of Patent:
October 24, 2023
Assignee:
Epizon Pharma, Inc.
Inventors:
James A. Tumlin, Paul L. Darke, John M. Rudey
Abstract: The invention provides an animal feed composition comprising microbial ?-amylase, for example, an animal feed composition comprising transgenic plant material comprising a microbial ?-amylase (e.g., a thermostable microbial ?-amylase). The invention further provides methods of increasing animal performance and/or the efficiency of feed utilization by an animal (e.g., for milk or meat production), comprising feeding to the animal an animal feed composition of the present invention.
Type:
Grant
Filed:
October 10, 2018
Date of Patent:
October 24, 2023
Assignee:
Syngenta Participations AG
Inventors:
Eileen Dorothea Watson, David Witherspoon, Tammiraj Kumar Iragavarapu
Abstract: The subject matter disclosed herein is generally directed to modulating anti-tumor T cell immunity by modulating steroidogenesis. Steroidogenesis may be modulated with inhibitors of enzymes that synthesize glucocorticoids in a tumor. The inhibitor may target Cyp11a1. The inhibitor may be metyrapone. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
Type:
Grant
Filed:
October 7, 2020
Date of Patent:
October 24, 2023
Assignees:
The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
Inventors:
Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
Abstract: The invention relates to polymorphic forms of the calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester. The calcium salt of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester is useful in the treatment of various conditions and disorders responsive to the inhibition of neutral endopeptidases.
Type:
Grant
Filed:
July 2, 2015
Date of Patent:
October 17, 2023
Assignee:
Novartis AG
Inventors:
David Hook, Bin Hu, Florian Karl Kleinbeck, Ulrich Meier, Sibylle Mueller, Jean-Paul Mutz, Jan Schlomach, Paul Allen Sutton, Liladhar Murlidhar Waykole, Bernhard Wietfeld
Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Abstract: The subject invention provides compounds as antitoxins for mitigating the toxic effects of algal toxins, e.g., brevetoxins. These compounds are mercaptan based compounds and derivatives that react rapidly with such toxins, e.g., brevetoxins and can be used to treat poisoning in a subject caused by such toxins. The subject invention also provides compositions comprising the mercaptan based compounds and derivatives for use to mitigate the toxic effects of brevetoxins. Further provided are methods of using the mercaptan based compounds and derivatives and compositions for treating and/or preventing brevetoxin poisoning in a subject such a human and marine animal.
Type:
Grant
Filed:
October 25, 2022
Date of Patent:
October 10, 2023
Assignee:
THE FLORIDA INTERNATIONAL UNIVERISTY BOARD OF TRUSTEES
Abstract: The invention relates generally to the field of medical treatment. More particularly, the invention relates to treating a subject in order to reduce levels of triglycerides or cortisol by the administration of pharmaceutical formulations.
Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
Type:
Grant
Filed:
July 8, 2020
Date of Patent:
September 19, 2023
Assignee:
CHEMOCENTRYX, INC.
Inventors:
Xi Chen, Pingchen Fan, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang, Dean Dragoli
Abstract: Compounds of the general Formula A-D-Y are disclosed with activity towards treating diseases related to inflammation, cancer, neurodegenerative diseases, and cardiovascular diseases. Pharmaceutical compositions, methods of making, and methods of use thereof are also described.
Abstract: The invention belongs to the technical field of medicine, and particularly relates to use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases. Through the research in the invention, it is found that the bromophenol-pyrazoline compounds inhibit replication of porcine coronaviruses at a cellular level, and can treat porcine coronavirus diseases (such as PEDV and TGEV) in clinical trials, greatly improving the survival rate of infected piglets, so the compounds can be used to prepare drugs for treating porcine coronavirus diseases.
Abstract: Methods of using a high-dose statin for treatment of AMD in a patient can be used to regress drusen and/or drusenoid pigment epithelial detachments (PEDs), to prevent atrophy of the RPE and/or one or more photoreceptors, to prevent vision loss and/or improve visual acuity, and/or to prevent progression from dry AMD to wet AMD.
Abstract: The present invention provides novel nanostructures comprising solution of PPSU20. Methods of preparing the novel PPSU nanostructures, and applications of such nanostructures are also provided.
Type:
Grant
Filed:
July 29, 2020
Date of Patent:
August 29, 2023
Assignee:
Northwestern University
Inventors:
Evan A. Scott, Sijia Yi, David Engman, Xiaomo Li
Abstract: Anti-aging compounds identified using the lead compounds violuric acid and 1-naphthoquinone-2-monoxime are described. The compounds are redox catalysts that appear to improve the function of hematopoietic stem cells. The compounds can be used to decrease the rate of aging in a subject, or to treat or decrease the risk of developing an age-related disease or disorder.
Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
Type:
Grant
Filed:
February 10, 2021
Date of Patent:
August 15, 2023
Assignee:
Celgene Corporation
Inventors:
Maria Soraya Carrancio Anton, Joshua Hansen, Courtney G. Havens, Antonia Lopez-Girona, Gang Lu, Lilly L. Wong
Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) tissue calcification in a subject with diabetes, chronic kidney disease, end stage renal failure, or a subject undergoing hemodialysis and/or receiving anticoagulant therapy. The invention further provides methods and compositions for reducing one or more symptoms of chronic obstructive pulmonary disorder (COPD), including using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7), for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) one or more symptoms of COPD.
Type:
Grant
Filed:
May 11, 2021
Date of Patent:
August 15, 2023
Assignee:
Epizon Pharma, Inc.
Inventors:
James A. Tumlin, Paul L. Darke, John M. Rudey
Abstract: In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
Abstract: A method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. A method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. A method of defining therapeutic doses of a psychedelic in clinical trials.
Type:
Grant
Filed:
April 8, 2021
Date of Patent:
August 8, 2023
Assignee:
Universitatsspital Basel
Inventors:
Matthias Emanuel Liechti, Friederike Sophie Holze
Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
Type:
Grant
Filed:
October 30, 2020
Date of Patent:
August 8, 2023
Assignee:
Purdue Research Foundation
Inventors:
Philip Stewart Low, Sumith A. Kularatne
Abstract: A compound of Structure (I): or a pharmaceutically acceptable salt thereof, alone or in combination with a second therapeutic agent, as well as methods of treating a PKM2-mediated disease or disorder using the same are provided herein.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
August 1, 2023
Assignee:
Sumitomo Pharma Oncology, Inc.
Inventors:
Steven L. Warner, David J. Bearss, Jason Marc Foulks